Madrigal Graham Number from 2010 to 2026
| MDGL Stock | USD 473.79 7.21 1.50% |
Graham Number | First Reported 2010-12-31 | Previous Quarter 195.71 | Current Value 173.97 | Quarterly Volatility 11.49390994 |
Check Madrigal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Madrigal Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 17.7 M, Other Operating Expenses of 818.7 M or Research Development of 285.8 M, as well as many indicators such as Price To Sales Ratio of 39.81, Dividend Yield of 0.0073 or PTB Ratio of 8.22. Madrigal financial statements analysis is a perfect complement when working with Madrigal Pharmaceuticals Valuation or Volatility modules.
Madrigal | Graham Number | Build AI portfolio with Madrigal Stock |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Madrigal Pharmaceuticals Correlation against competitors. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (12.93) | Revenue Per Share | Quarterly Revenue Growth 3.62 | Return On Assets | Return On Equity |
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.